Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with platinum-etoposide and thoracic radiotherapy for extensive-stage small cell lung cancer
ACTRN12621000586819Phase 2Recruiting
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Feb 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab, etoposide, carboplatin and cisplatin in small cell lung cancer (SCLC) (2 arms), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoints: Safety of chemo-immunotherapy with concurrent thoracic radiotherapy and Feasibility of chemo-immunotherapy with concurrent thoracic radiotherapy. Started Feb 2022; status: recruiting.
02
Drugs
durvalumabetoposidecarboplatincisplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ACTRN12621000586819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000586819.